DK1638574T3 - Nye farmaceutiske anvendelser af staurosporin-derivater - Google Patents

Nye farmaceutiske anvendelser af staurosporin-derivater

Info

Publication number: DK1638574T3
Authority: DK; Denmark
Prior art keywords: warm; pharmaceutical applications; new pharmaceutical; derivatives; staurosporin derivatives
Prior art date: 2003-06-18

Application number

DK04740016.3T

Other languages

English (en)

Inventor

Steven Coutre

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-18

Filing date

2004-06-17

Publication date

2010-08-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33539193&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1638574(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-06-17 Application filed by Novartis Ag filed Critical Novartis Ag

2010-08-02 Application granted granted Critical

2010-08-02 Publication of DK1638574T3 publication Critical patent/DK1638574T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Oncology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Child & Adolescent Psychology (AREA)
Otolaryngology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK04740016.3T 2003-06-18 2004-06-17 Nye farmaceutiske anvendelser af staurosporin-derivater DK1638574T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US47957503P	2003-06-18	2003-06-18
PCT/EP2004/006562 WO2004112794A2 (en)	2003-06-18	2004-06-17	New pharmaceutical uses of staurosporine derivatives

Publications (1)

Publication Number	Publication Date
DK1638574T3 true DK1638574T3 (da)	2010-08-02

Family

ID=33539193

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04740016.3T DK1638574T3 (da)	2003-06-18	2004-06-17	Nye farmaceutiske anvendelser af staurosporin-derivater

Country Status (24)

Country	Link
US (2)	US8575146B2 (da)
EP (1)	EP1638574B1 (da)
JP (2)	JP5057780B2 (da)
CN (2)	CN101164539A (da)
AT (1)	ATE464052T1 (da)
AU (1)	AU2004248909B2 (da)
BE (1)	BE2017C067I2 (da)
BR (1)	BRPI0411563B8 (da)
CA (2)	CA2785950A1 (da)
CY (2)	CY1110179T1 (da)
DE (1)	DE602004026578D1 (da)
DK (1)	DK1638574T3 (da)
ES (1)	ES2344700T3 (da)
FR (1)	FR17C1063I2 (da)
HK (1)	HK1095519A1 (da)
HU (1)	HUS000503I2 (da)
LU (1)	LUC00055I9 (da)
MX (1)	MXPA05013722A (da)
NL (1)	NL300917I2 (da)
PL (1)	PL1638574T3 (da)
PT (1)	PT1638574E (da)
SI (1)	SI1638574T1 (da)
TW (1)	TWI324604B (da)
WO (1)	WO2004112794A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI324604B (en) *	2003-06-18	2010-05-11	Novartis Ag	New use of staurosporine derivatives
US20060014165A1 (en) *	2003-07-14	2006-01-19	Decode Genetics Ehf.	Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
CN1882344A (zh)	2003-11-18	2006-12-20	诺瓦提斯公司	Kit突变形式的抑制剂
WO2005115385A1 (en) *	2004-05-24	2005-12-08	Ab Science	Use of c-kit inhibitors for treating acne
CN103251953A (zh) *	2004-07-19	2013-08-21	约翰·霍普金斯大学	供免疫抑制的flt3抑制剂
MX2007001155A (es) *	2004-07-29	2007-08-14	Creabilis Therapeutics Spa	Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
GB0419159D0 (en) *	2004-08-27	2004-09-29	Novartis Ag	Organic compounds
JP5129123B2 (ja) *	2005-05-02	2013-01-23	ノバルティスアーゲー	全身性肥満細胞症の処置のためのピリミジルアミノベンズアミド誘導体の使用
DE602006013826D1 (de) *	2005-07-20	2010-06-02	Peter Valent	Zusammensetzungen zur behandlung von systemischer mastocytose
EP1951255A1 (en) *	2005-11-14	2008-08-06	Universität Zürich	Staurosporine derivatives for use in alveolar rhabdomyosarcoma
WO2009092442A1 (en) *	2008-01-23	2009-07-30	Universidad De Barcelona	Treatment of portal hypertension and related conditions by combined inhibition of the vegf and pdgf signalling pathways
US8802099B2 (en) *	2010-11-10	2014-08-12	National Jewish Health	Methods to treat allergic conditions
CR20210287A (es)	2018-11-01	2022-02-15	Syros Pharmaceuticals Inc	Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
WO2020097261A1 (en) *	2018-11-06	2020-05-14	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	New compositions and methods for treating beta-globinopathies
US11839619B2 (en) *	2019-09-16	2023-12-12	The Regents Of The University Of California	Methods for treatment of pediatric systemic mastocytosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4639455A (en) *	1984-10-02	1987-01-27	Key Pharmaceuticals, Inc.	Means of aiding in the prevention of sudden infant death syndrome
JPH0826037B2 (ja) *	1987-01-22	1996-03-13	協和醗酵工業株式会社	生理活性物質ｋ−２５２の誘導体
US5093330A (en) *	1987-06-15	1992-03-03	Ciba-Geigy Corporation	Staurosporine derivatives substituted at methylamino nitrogen
CA2046801C (en)	1990-08-07	2002-02-26	Peter D. Davis	Substituted pyrroles
DK0518468T3 (da) *	1991-05-09	2000-01-31	Neurim Pharma 1991	Melatoninholdige sammensætninger
AR004480A1 (es)	1995-04-06	1998-12-16	Amico Derin C D	Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
NZ333441A (en) *	1996-06-25	1999-05-28	Cephalon Inc	Use of k-252a derivatives for the treatment of peripheral or central nerve disorders, and cytokine overproduction
US6093740A (en) *	1997-04-30	2000-07-25	Eli Lilly And Company	Therapeutic treatment for skin disorders
WO1999062537A1 (en) *	1998-06-04	1999-12-09	The Rockefeller University	Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
GB9903547D0 (en) *	1999-02-16	1999-04-07	Novartis Ag	Organic compounds
DE60112611T2 (de) *	2000-12-08	2006-06-14	Ortho Mcneil Pharm Inc	Makroheterocyclische verbindungen als kinase inhibitoren
GB0108606D0 (en) *	2001-04-05	2001-05-23	Novartis Ag	Organic compounds
EP1471907B1 (en) *	2001-06-29	2008-07-16	AB Science	Use of c-kit inhibitors for treating autoimmune diseases
US20030091974A1 (en) *	2001-06-29	2003-05-15	Alain Moussy	Method for screening compounds capable of depleting mast cells
CN1582150B (zh)	2001-10-30	2011-09-07	诺瓦提斯公司	作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
US6998391B2 (en)	2002-02-07	2006-02-14	Supergen.Inc.	Method for treating diseases associated with abnormal kinase activity
EP1645286A1 (en) *	2003-04-18	2006-04-12	Kyowa Hakko Kogyo Co., Ltd.	Drug for nerve regeneration
JPWO2004093910A1 (ja) *	2003-04-22	2006-07-13	アステラス製薬株式会社	ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
TWI324604B (en) *	2003-06-18	2010-05-11	Novartis Ag	New use of staurosporine derivatives
CN1882344A (zh)	2003-11-18	2006-12-20	诺瓦提斯公司	Kit突变形式的抑制剂

2004
- 2004-06-16 TW TW093117368A patent/TWI324604B/zh active
- 2004-06-17 MX MXPA05013722A patent/MXPA05013722A/es active IP Right Grant
- 2004-06-17 AT AT04740016T patent/ATE464052T1/de active
- 2004-06-17 AU AU2004248909A patent/AU2004248909B2/en active Active
- 2004-06-17 PL PL04740016T patent/PL1638574T3/pl unknown
- 2004-06-17 EP EP04740016A patent/EP1638574B1/en active Active
- 2004-06-17 PT PT04740016T patent/PT1638574E/pt unknown
- 2004-06-17 DE DE602004026578T patent/DE602004026578D1/de active Active
- 2004-06-17 SI SI200431450T patent/SI1638574T1/sl unknown
- 2004-06-17 CA CA2785950A patent/CA2785950A1/en not_active Abandoned
- 2004-06-17 CN CNA2007101658371A patent/CN101164539A/zh active Pending
- 2004-06-17 US US10/560,669 patent/US8575146B2/en active Active
- 2004-06-17 JP JP2006515982A patent/JP5057780B2/ja active Active
- 2004-06-17 ES ES04740016T patent/ES2344700T3/es active Active
- 2004-06-17 DK DK04740016.3T patent/DK1638574T3/da active
- 2004-06-17 CN CNB2004800168219A patent/CN100457111C/zh active Active
- 2004-06-17 BR BRPI0411563A patent/BRPI0411563B8/pt not_active Application Discontinuation
- 2004-06-17 CA CA2527703A patent/CA2527703C/en active Active
- 2004-06-17 WO PCT/EP2004/006562 patent/WO2004112794A2/en active Application Filing
2007
- 2007-01-18 HK HK07100635.4A patent/HK1095519A1/xx unknown
2010
- 2010-07-06 CY CY20101100627T patent/CY1110179T1/el unknown
2012
- 2012-04-26 JP JP2012101493A patent/JP2012144572A/ja active Pending
2013
- 2013-06-27 US US13/929,438 patent/US20130289018A1/en not_active Abandoned
2017
- 2017-12-07 NL NL300917C patent/NL300917I2/nl unknown
- 2017-12-12 LU LU00055C patent/LUC00055I9/fr unknown
- 2017-12-14 HU HUS1700053C patent/HUS000503I2/hu unknown
- 2017-12-19 BE BE2017C067C patent/BE2017C067I2/fr unknown
- 2017-12-22 CY CY2017048C patent/CY2017048I1/el unknown
- 2017-12-28 FR FR17C1063C patent/FR17C1063I2/fr active Active

Also Published As

Publication number	Publication date
CA2527703A1 (en)	2004-12-29
HUS000503I2 (hu)	2021-03-29
AU2004248909B2 (en)	2008-05-08
EP1638574A2 (en)	2006-03-29
CY1110179T1 (el)	2015-01-14
AU2004248909A1 (en)	2004-12-29
CN100457111C (zh)	2009-02-04
TWI324604B (en)	2010-05-11
EP1638574B1 (en)	2010-04-14
CY2017048I2 (el)	2018-09-05
JP5057780B2 (ja)	2012-10-24
LUC00055I2 (da)	2018-02-21
ES2344700T3 (es)	2010-09-03
PT1638574E (pt)	2010-07-14
BRPI0411563B1 (pt)	2019-09-24
JP2006527727A (ja)	2006-12-07
MXPA05013722A (es)	2006-03-08
JP2012144572A (ja)	2012-08-02
FR17C1063I2 (fr)	2019-05-03
LUC00055I9 (da)	2022-11-09
SI1638574T1 (sl)	2010-08-31
BE2017C067I2 (da)	2023-08-09
WO2004112794A3 (en)	2005-06-16
TW200512213A (en)	2005-04-01
BRPI0411563A (pt)	2006-08-01
DE602004026578D1 (de)	2010-05-27
CN101164539A (zh)	2008-04-23
CA2785950A1 (en)	2004-12-29
FR17C1063I1 (da)	2018-02-16
LUC00055I1 (da)	2017-12-14
US20070299049A1 (en)	2007-12-27
US8575146B2 (en)	2013-11-05
WO2004112794A2 (en)	2004-12-29
BRPI0411563B8 (pt)	2021-05-25
CA2527703C (en)	2012-10-23
NL300917I2 (nl)	2018-01-09
ATE464052T1 (de)	2010-04-15
US20130289018A1 (en)	2013-10-31
HUS1700053I1 (hu)	2018-01-29
CN1805749A (zh)	2006-07-19
NL300917I1 (nl)	2017-12-12
PL1638574T3 (pl)	2010-09-30
HK1095519A1 (en)	2007-05-11
CY2017048I1 (el)	2018-09-05

Publication	Publication Date	Title
FR17C1063I2 (fr)	2019-05-03	Nouvelle utilisation de derives de staurosporine
NO20055216L (no)	2005-12-08	Nye hydroksamater som terapeutiske midler
DE60140814D1 (de)	2010-01-28	N-phenyl-2-pyrimidine-amine derivatives
SG170101A1 (en)	2011-04-29	2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
EA200800798A1 (ru)	2008-10-30	Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
ATE411022T1 (de)	2008-10-15	Pyridylpyrrol-derivate als wirksame kinase-hemmer
EA200970595A1 (ru)	2010-02-26	Производные замещенных индазолов, активные в качестве ингибиторов киназ
NO20084328L (no)	2008-11-18	Nye forbindelser
ATE514699T1 (de)	2011-07-15	Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
NO20092737L (no)	2009-09-18	Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer
NO20061253L (no)	2006-05-18	Acetylenderivater som inhibitorer av histon deacetylase
EA200971053A1 (ru)	2010-06-30	Способы лечения кожных язв
CY1108932T1 (el)	2014-07-02	Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ATE487720T1 (de)	2010-11-15	5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
ATE529417T1 (de)	2011-11-15	3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält
BR0313718A (pt)	2005-07-12	Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
NO20065551L (no)	2007-02-05	Anvendelse av opoid reseptor antagonistforbindelser for forhindring og/eller behandling av sykdommer assosiert med malet calcineurin
EA200701086A1 (ru)	2007-12-28	Производные изоксазола, их фармацевтические композиции и способ лечения невропатической боли